Literature DB >> 7620185

Engraftment of bone marrow cells into normal unprepared hosts: effects of 5-fluorouracil and cell cycle status.

H S Ramshaw1, S S Rao, R B Crittenden, S O Peters, H U Weier, P J Quesenberry.   

Abstract

Bone marrow from animals treated with 5-fluorouracil (5FU) competes equally with normal marrow when assessed in vivo in an irradiated mouse, but shows markedly defective engraftment when transplanted into noncytoablated hosts. Using Southern Blot analysis and a Y-chromosome specific probe, we determined the level of engraftment of male donor cells in the bone marrow, spleen, and thymus of unprepared female hosts. We have confirmed the defective engraftment of marrow harvested 6 days after 5FU (FU-6) and transplanted into unprepared hosts and shown that this defect is transient; by 35 days after 5FU (FU-35), engraftment has returned to levels seen with normal marrow. FU-6 marrow represents an actively cycling population of stem cells, and we hypothesize that the cycle status of the stem cell may relate to its capacity to engraft in the nonirradiated host. Accordingly, we have evaluated the cycle status of engrafting normal and FU-6 marrow into normal hosts using an in vivo hydroxyurea technique. We have shown that those cells engrafting from normal marrow and over 70% of the cells engrafting from FU-6 marrow were quiescent, demonstrating no killing with hydroxyurea. We have also used fluorescent in situ hybridization (FISH) analysis with a Y-chromosome probe and demonstrated that normal and post-5FU engraftment patterns in peripheral blood were similar to those seen in bone marrow, spleen, and thymus. Altogether these data indicate that cells engrafting in normal, unprepared hosts are dormant, and the defect that occurs after 5FU is concomitant with the induction of these cells to transit the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620185

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  The new stem cell biology.

Authors:  Peter J Quesenberry; Gerald A Colvin; Jean-Francois Lambert; Angela E Frimberger; Mark S Dooner; Christina I Mcauliffe; Caroline Miller; Pamela Becker; Evangelis Badiavas; Vincent J Falanga; Gerald Elfenbein; Lawrence G Lum
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

Review 2.  Chemokine-mobilized adult stem cells; defining a better hematopoietic graft.

Authors:  L M Pelus; S Fukuda
Journal:  Leukemia       Date:  2007-11-01       Impact factor: 11.528

3.  Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation.

Authors:  Michael J Nemeth; Lilia Topol; Stacie M Anderson; Yingzi Yang; David M Bodine
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-19       Impact factor: 11.205

Review 4.  Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand.

Authors:  Louis M Pelus
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

Review 5.  Stem cell homing: rolling, crawling, and nesting.

Authors:  P J Quesenberry; P S Becker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

6.  Chiaroscuro hematopoietic stem cell.

Authors:  P Quesenberry; M Habibian; M Dooner; S Zhong; J Reilly; S Peters; P Becker; C Grimaldi; J Carlson; P Reddy; S Nilsson; F M Stewart
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

7.  Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates.

Authors:  M Takatoku; S Sellers; B A Agricola; M E Metzger; I Kato; R E Donahue; C E Dunbar
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

8.  Influence of timing of administration of 5-fluorouracil to donors on bone marrow engraftment in nonmyeloablated hosts.

Authors:  L D'Hondt; J Carlson; B Benoit; J Reilly; C Grimaldi; J Wuu; J F Lambert; M S Dooner; P J Quesenberry
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

Review 9.  Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.

Authors:  Carrie Gibbons; Megan Sykes
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

10.  The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment.

Authors:  Seiji Fukuda; Huimin Bian; Andrew G King; Louis M Pelus
Journal:  Blood       Date:  2007-04-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.